BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10459811)

  • 1. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans.
    Barchiesi F; Gallo D; Caselli F; Di Francesco LF; Arzeni D; Giacometti A; Scalise G
    J Antimicrob Chemother; 1999 Jul; 44(1):65-70. PubMed ID: 10459811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.
    Schwarz P; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3361-4. PubMed ID: 14506059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of posaconazole and flucytosine against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Najvar LK; Bocanegra R; Caselli F; Di Cesare S; Giannini D; Di Francesco LF; Giacometti A; Carle F; Scalise G; Graybill JR
    Antimicrob Agents Chemother; 2001 May; 45(5):1355-9. PubMed ID: 11302795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.
    Nguyen MH; Barchiesi F; McGough DA; Yu VL; Rinaldi MG
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1691-5. PubMed ID: 7486902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
    Franzot SP; Casadevall A
    Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
    Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
    Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.
    Mosquera J; Sharp A; Moore CB; Warn PA; Denning DW
    J Antimicrob Chemother; 2002 Aug; 50(2):189-94. PubMed ID: 12161398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
    Warnock DW; Johnson EM; Rogers TR
    J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
    Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
    Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
    Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
    J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera.
    Vitale RG; Afeltra J; de Hoog GS; Rijs AJ; Verweij PE
    J Antimicrob Chemother; 2003 May; 51(5):1297-300. PubMed ID: 12697648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
    Abdel-Salam HA
    Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Pinus sylvestris L. (Pinaceae), Origanum vulgare L. (Lamiaceae), and Thymus vulgaris L. (Lamiaceae) essential oils and their main components to enhance itraconazole activity against azole susceptible/not-susceptible Cryptococcus neoformans strains.
    Scalas D; Mandras N; Roana J; Tardugno R; Cuffini AM; Ghisetti V; Benvenuti S; Tullio V
    BMC Complement Altern Med; 2018 May; 18(1):143. PubMed ID: 29724221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method.
    López-Jodra O; Torres-Rodríguez JM; Méndez-Vásquez R; Ribas-Forcadell E; Morera-López Y; Baró-Tomás T; Alia-Aponte C
    J Antimicrob Chemother; 2000 May; 45(5):645-9. PubMed ID: 10797087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
    Schwarz P; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro.
    Feldmesser M; Mukherjee J; Casadevall A
    J Antimicrob Chemother; 1996 Mar; 37(3):617-22. PubMed ID: 9182119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.